Shu Hui Chen
Corporate Officer/Principal chez WUXI PHARMATECH (CAYMAN) INC. (ADR)
Profil
Shu Hui Chen is currently the Executive Vice President & Head-DDSU at Wuxi PharmaTech (Cayman), Inc. Prior to this, he held positions at Vion Pharmaceuticals, Inc. as Associate Director-Chemistry from 1995 to 1997, Bristol Myers Squibb Co. as Senior Research Investigator in 1995, and Eli Lilly & Co. as Research Advisor from 1998 to 2004.
He also served as Vice President at WuXi AppTec Co., Ltd.
from 2004 to 2024.
Dr. Chen obtained his doctorate degree from Yale University in 1990 and his undergraduate degree from Fudan University in 1985.
Postes actifs de Shu Hui Chen
| Sociétés | Poste | Début |
|---|---|---|
| WUXI PHARMATECH (CAYMAN) INC. (ADR) | Corporate Officer/Principal | - |
Anciens postes connus de Shu Hui Chen
| Sociétés | Poste | Fin |
|---|---|---|
| WUXI APPTEC CO., LTD. | Chief Tech/Sci/R&D Officer | 23/03/2016 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/2004 |
Vion Pharmaceuticals, Inc.
 Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Corporate Officer/Principal | 01/01/1997 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/1995 |
Formation de Shu Hui Chen
| Yale University | Doctorate Degree |
| Fudan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| WUXI APPTEC CO., LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Health Technology |
Wuxi PharmaTech (Cayman), Inc.
 Wuxi PharmaTech (Cayman), Inc. Pharmaceuticals: MajorHealth Technology Wuxi PharmaTech (Cayman), Inc. engages in the provision of research and development outsourcing services for the pharmaceutical, biotechnology and medical device industries. It operates through the laboratory services and manufacturing services segments. The laboratory services segment offers pharmaceutical and biotech services including discovery and medicinal chemistry, discovery biology, safety pharmacology, bioanalytical services, process research, formulation and toxicology laboratory services, as well as testing services for biologics, medical devices and combination products. The manufacturing services segment involves the production of intermediates and active pharmaceutical ingredients for or preclinical and clinical trials of small-molecule and commercial products; and biologics. The company was founded by Ge Li, Xiao Zhong Liu, Zhao Hui Zhang and Ning Zhao in 2000 and is headquartered in Shanghai, China. | Health Technology |
